Αποτελέσματα Αναζήτησης
26 Φεβ 2024 · The study, published in Vaccine, confirmed previously identified rare safety signals for myocarditis and pericarditis after a mRNA vaccine (Pfizer and Moderna) and Guillain-Barré syndrome and cerebral venous sinus thrombosis (CVST) after viral vector vaccines (AstraZeneca).1
27 Φεβ 2024 · The Vaccine study confirmed that the Moderna and Pfizer/BioNTech vaccines are linked in rare cases to myocarditis and pericarditis, conditions involving inflammation of the heart muscle and...
8 Απρ 2022 · Vaccine effectiveness decreased more among individuals aged 55 years or older and among those with comorbidities. 135 932 individuals aged 55 years or older received a booster (2123 [1·6%] of whom tested positive).
7 Νοε 2023 · In conclusion, this study investigated the impact of sex and age on mRNA COVID-19 vaccine-related side effects in booster-vaccinated adults (i.e. adults who received the third vaccine dose).
15 Οκτ 2022 · There was an increased risk of severe COVID-19 outcomes 9 weeks or more after receiving a booster dose of BNT162b2 or mRNA-1273 vaccine (≥9 weeks vs 3–5 weeks; aRR 1·20 [95% CI 1·07–1·35]).
11 Οκτ 2021 · While the Oxford-AstraZeneca and Pfizer-BioNTech vaccines as a single dose were associated with a relatively low reduction in the rate of SARS-CoV-2 infection at 3 months of 15% and 31% compared to being unvaccinated, respectively, the effect estimate crossed the null for the Oxford-AstraZeneca vaccine.
These findings are consistent with and expand on the results from the phase 3 trials for Pfizer-BionTech and Moderna, which showed that vaccine side effects were more common after the second dose than after the first dose.
